Treatment Strategies to Optimize Timing of Second Line Therapy and Identifying and Addressing Symptom Management to Improve Outcomes for Patients with PBC

1. Which of the following statements about treatments for PBC is CORRECT?

a. It is particularly important to treat cirrhotic PBC patients with second-line therapy because of their high risk of progression to end-stage disease

b. UDCA therapy should be stopped when patients start second-line therapy

c. Fatigue is a side-effect of obeticholic acid

d. UDCA therapy should be started immediately after a diagnosis of PBC

e. PBC is a more aggressive disease in older patients

2. Which of the following statements about PBC symptoms is INCORRECT?

a. Elafibranor will typically improve itch in PBC but not fatigue

b. Rifampicin is a second-line treatment for PBC itch

c. Itch improves in most people treated with UDCA

d. Sleep disturbance is common in PBC and contributes to symptom impact

e. Bezafibrate use for treatment of itch should be avoided in people with renal impairment

Course Catalog

By Category

By Course Type

About AcademicCME

Claim your AMA PRA Category 1 Credit(s), CNE Contact Hour(s) or CPE Contact Hour(s) (CEUs) credit

Pre-Test

course Faculty

Related Courses

© 2024 AcademicCME. All rights reserved.